Scrip and IQVia explore how Brexit will impact clinical trials, product launches and funding in the UK.

As we enter a new year, Scrip reviews some of the biggest overall themes which attracted our readers over the last 12 months.

From ongoing progress in IO to revolutions in AI, and from pricing headaches to new therapies for migraine: Scrip has gleaned from experts and industry executives their expectations and predictions for 2018's hot topics. Here is our digest.

MSD's R&D head Roger Perlmutter and Sir John Bell tell Scrip the UK government needs to offer better manufacturing incentives to the life science sector and also encourage more efficient drug innovation there.

Nearly 18 months after the UK voted to leave the European Union, pharmaceutical companies and regulators are still in the dark as to what kind of regulatory arrangements will exist between the two parties after Brexit takes place in March 2019.

The UK pharmaceutical industry has welcomed the announcement that Brexit talks are to move on to trade deal discussions, but says a regulatory cooperation agreement and a fixed transition period are essential to safeguard European supply chains. Several pharma executives outlined some of their key concerns at a parliamentary committee hearing on Dec. 5.